{
    "organizations": [],
    "uuid": "f49f2911eb120d75f7260c95b26fd62645de03fc",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-keryx-biopharmaceuticals-sees-tota/brief-keryx-biopharmaceuticals-sees-total-revenue-for-qtr-ended-march-31-2018-between-21-0-mln-and-22-5-mln-idUSFWN1S70XR",
    "ord_in_thread": 0,
    "title": "BRIEF-Keryx Biopharmaceuticals Sees Total Revenue For Qtr Ended March 31, 2018 Between $21.0 Mln And $22.5 Mln",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30 (Reuters) - Keryx Biopharmaceuticals Inc:\n* KERYX BIOPHARMACEUTICALS SEES TOTAL REVENUE FOR QUARTER ENDED MARCH 31, 2018 OF BETWEEN $21.0 MILLION AND $22.5 MILLION - SEC FILING\n* SAYS CEO AND PRESIDENT GREGORY MADISON RESIGNED * APPOINTED JODIE MORRISON AS INTERIM CHIEF EXECUTIVE OFFICER\n* REDUCED SIZE OF BOARD FROM EIGHT DIRECTORS TO SEVEN DIRECTORS Source text: [ bit.ly/2w0gKQT ] Further company coverage:\n ",
    "published": "2018-04-30T20:40:00.000+03:00",
    "crawled": "2018-05-01T20:28:31.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "keryx",
        "biopharmaceuticals",
        "inc",
        "keryx",
        "biopharmaceuticals",
        "see",
        "total",
        "revenue",
        "quarter",
        "ended",
        "march",
        "million",
        "million",
        "sec",
        "filing",
        "say",
        "ceo",
        "president",
        "gregory",
        "madison",
        "resigned",
        "appointed",
        "jodie",
        "morrison",
        "interim",
        "chief",
        "executive",
        "officer",
        "reduced",
        "size",
        "board",
        "eight",
        "director",
        "seven",
        "director",
        "source",
        "text",
        "company",
        "coverage"
    ]
}